What precautions should I take while taking Valcyte?

Valganciclovir/Valcyte is an oral antiviral drug used for the prevention of cytomegalovirus infection after organ transplantation and the treatment of cytomegalovirus eye infection in adults with acquired immunodeficiency syndrome (AIDS).

What precautions should be taken while taking Valganciclovir/Vansevir (Valcyte)?

1.Occurrenceblood toxicity. Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure, including aplastic anemia, have been reported in patients receivingvalganciclovir. If the absolute neutrophil count is lower than 500 cells/liters, the platelet count is lower than 25, 000 cells/liters or the hemoglobin is lower than 8 g/dL, the use of valganciclovir should be avoided. Valganciclovir should also be used with caution in patients with preexisting cytopenias and in patients receiving myelosuppressive drugs or radiation therapy. Cytopenia may occur at any time during treatment and may worsen with continued administration. Cell counts usually begin to recover within 3 to 7 days after stopping the drug. Hematopoietic growth factor therapy may be considered in patients with severe leukopenia, neutropenia, anemia, or thrombocytopenia. Because neutropenia, anemia, and thrombocytopenia frequently occur in patients receiving valganciclovir, complete blood counts, differential counts, and platelet counts should be obtained frequently, especially in infants, patients with renal impairment, patients with a history of leukopenia with ganciclovir or other nucleoside analogues, or those with neutrophil counts below 1000cells/ L’s patients.

2.Acute renal failure may occur in elderly patients(with or without decreased renal function), patients receiving concomitant nephrotoxic drugs, or patients with insufficient fluid intake. Use with caution in elderly patients or patients taking nephrotoxic drugs. In patients with renal impairment, reduce the dose and monitor renal function.

3.Impaired fertility may occur. Valganciclovir may temporarily or permanently inhibit male spermatogenesis and may inhibit female fertility at recommended human doses. Inform patients that use of valganciclovir may impair fertility.

4.Fetal toxicity may occur. Animal studies have found that valganciclovir may cause fetal toxicity when taken by pregnant women. When pregnant rabbits take valganciclovir, the dose is 2 times the human exposure dose (based on AUC), which can cause multiple fetal organ malformations. Maternal and fetal toxicity has also been observed in pregnant mice and rabbits. Therefore,valganciclovir has the potential to cause birth defects. Female patients taking valganciclovir and women whose male partners are taking valganciclovir should avoid becoming pregnant. Given the potential risk to the fetus, females of childbearing potential should be advised to use effective contraception during treatment and for at least 30 days after treatment with valganciclovir. Likewise, men should be advised to use condoms during valganciclovir treatment and for at least 90 days after treatment. The retail price of the Turkish version of the original drug in pharmacies0.45g*60tablets2more than a thousand. The retail price of original medicine in India is about 0.45g*60 tablets4 around one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.